Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / March / A New Molecular Barcode for Cancer
Oncology Liquid biopsy Biochemistry and molecular biology Molecular Pathology

A New Molecular Barcode for Cancer?

Pan-cancer analysis identifies cancer-specific small RNAs with tissue-of-origin and liquid biopsy potential

03/04/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Institutions

Share

Top Institutions in Molecular Oncology and Cancer Biomarker Research

Leading institutions employ large-scale RNA sequencing, bioinformatics, and translational cancer biology approaches to discover and validate novel RNA biomarkers, integrating molecular profiling with clinical oncology to advance liquid biopsy technologies and cancer diagnostics.

  • #1

    Memorial Sloan Kettering Cancer Center

    New York, NY

    MSKCC is a global leader in cancer genomics and liquid biopsy research, with extensive expertise in RNA sequencing and biomarker discovery, supported by robust translational programs linking molecular findings to clinical applications.

    Key Differentiators

    • Molecular Oncology
    • Cancer Genomics
    • Liquid Biopsy
  • #2

    Dana-Farber Cancer Institute

    Boston, MA

    Dana-Farber has a strong track record in molecular cancer research and biomarker development, with significant contributions to understanding noncoding RNAs and their roles in oncogenesis and cancer diagnostics.

    Key Differentiators

    • Cancer Biology
    • Molecular Diagnostics
    • Translational Research
  • #3

    Broad Institute of MIT and Harvard

    Cambridge, MA

    The Broad Institute excels in large-scale genomic and transcriptomic data analysis, developing novel computational methods to identify cancer-specific RNA signatures and orphan transcripts with clinical relevance.

    Key Differentiators

    • Genomics
    • Bioinformatics
    • Cancer Molecular Profiling
  • #4

    Johns Hopkins University School of Medicine

    Baltimore, MD

    Johns Hopkins has a strong focus on molecular pathology and liquid biopsy technologies, with notable contributions to RNA biomarker validation and cancer subtype classification using transcriptomic data.

    Key Differentiators

    • Cancer Genomics
    • Molecular Pathology
    • Liquid Biopsy
  • #5

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    UCSF is recognized for its cutting-edge research in cancer genomics and molecular oncology, including pioneering studies on noncoding RNAs and their functional roles in cancer biology and diagnostics.

    Key Differentiators

    • Cancer Genomics
    • Molecular Oncology
    • Translational Medicine

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

A Light in the Darkness
Liquid biopsy
A Light in the Darkness

March 4, 2022

2 min read

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

Biomarkers: The Bigger Picture
Liquid biopsy
Biomarkers: The Bigger Picture

April 27, 2022

1 min read

To unlock patient care, pathologists must focus on molecular pathology and ensure efficiency and effectiveness to improve testing. With this testing, patients can benefit from the best treatment to combat their disease.

Benchmarking… Liquid Biopsy
Liquid biopsy
Benchmarking… Liquid Biopsy

May 13, 2022

1 min read

A look at the last five years of publishing on liquid biopsy

Does Your Blood Know You Have Cancer?
Liquid biopsy
Does Your Blood Know You Have Cancer?

July 25, 2022

2 min read

Detection and monitoring are crucial for melanoma outcomes – could a blood test revolutionize both?

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.